English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/177663
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Modulation of the enzyme soluble epoxide hydrolase as a therapeutic target against neurodegenerative diseases

AuthorsAlmenara, Lidia; Corpas, Rubén ; Suñol, Cristina ; Vázquez, S.; Galdeano, Carles; Pallàs, Mercè; Sanfeliu, Coral
KeywordsSoluble epoxide hydrolase
Inhibitor
Epoxyeicosatrienoic acids
Neuroinflammation
Issue Date12-Nov-2018
CitationXI Simposi de Neurobiologia (2018)
AbstractNeurodegenerative diseases cursing with chronic inflammatory conditions represent a major health problem due to the global increase in life expectancy and age-related diseases. Thus, there is an urgent need for new approaches to mitigate neuroinflammation. Epoxyeicosatrienoic acids (EETs) are endogenous mediators that have several potentially protective functions including anti-inflammatory effects. EETs beneficial effects disappear when the enzyme soluble Epoxide Hydrolase (sEH) metabolizes them to the corresponding dihydroxyeicosatrienoic acids. Therefore, sEH enzyme is emerging as a promising pharmacological target, because its inhibition allows increasing EETs and keeping them active. The aim of the present study was to determine the half maximal inhibitory concentration (IC50) of a newly synthetized sEH inhibitor (sEHi) series, agents A01, A02, A03, A04, A05 and A06, and study their toxicity and anti-inflammatory effects. Neuroblastoma SH-SY5Y cell cultures were used to the IC50 calculation and the safety level of each sEHi. To study the anti-inflammatory effects, lipopolysaccharide stimulated microglial-like BV2 cells were used to obtain conditioned media with the proinflammatory mediators. Modulatory effects on the inflammatory pathways iNOS and NFĸB, and the release of cytokines were explored using techniques of Western Blot, immunocytochemistry and ELISA. All agents showed higher inhibitory potency than the reference compound 1-(1-propionylpiperidin-4-yl)- 3-[4-(trifluoromethoxy)phenyl]urea (TPPU) and generally low cytotoxicity. They also showed promising anti-inflammatory properties. In this way, the newly synthesized sEHi agents could be a new therapy against the neuroinflammation present in neurodegenerative diseases as Alzheimer’s disease, and in other neurological diseases with an inflammatory component.
DescriptionTrabajo presentado en el XI Simposi de Neurobiologia: Future technical advances, organizado por la Socitat Catalana de Biologia, en Barcelona, los días 12 y 13 de noviembre de 2018
URIhttp://hdl.handle.net/10261/177663
Appears in Collections:(IIBB) Comunicaciones congresos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.